Press Releases

 
Press Releases
  Date Title and Summary View
Apr 17, 2017
MONROVIA, Calif., April 17, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman, Ph.D., chief executive officer of Neurocrine Biosciences, has been appointed to Xencor's Board of Direct...
PDF
Mar 15, 2017
MONROVIA, Calif., March 15, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the...
PDF
Mar 6, 2017
MONROVIA, Calif., March 6, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Bruce L.A. Carter, Ph.D., will not stand for reelection to the Company's Board of Directors at the 2017 Annual Meeting ...
PDF
Mar 1, 2017
MONROVIA, Calif., March 1, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that data from preclinical studies on XmAb®18087 and additional candidates deploying its XmAb® bispecific and half...
PDF
Feb 28, 2017
MONROVIA, Calif., Feb. 28, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2016 and provi...
PDF
Feb 22, 2017
MONROVIA, Calif., Feb. 22, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and full year 2016 financial results after the market clo...
PDF
Feb 18, 2017
MONROVIA, Calif., Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H. Stone, M.D., Ph.D. from the Massachusetts General Hospital, ...
PDF
Feb 9, 2017
MONROVIA, Calif., Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the L...
PDF
Dec 6, 2016
MONROVIA, Calif., Dec. 6, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 5,272,750 shares of its common stock, including 687,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock.  All of t...
PDF
Dec 1, 2016
MONROVIA, Calif., Dec. 1, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 4,585,000 shares of its common stock, offered at a price to the public of $24.00 per share. The gross proceeds from this offering to Xencor are expected to be approximately $110 million, before deducting under...
PDF
Page: FirstPrevious
2
... NextLast
Xencor © Copyright 2017